Exploring the human tear fluid: Discovery of new biomarkers in multiple sclerosis

Proteomics - Clinical Applications

Volumn 8, Issue 3-4, 2014, Pages 185-194

  Salvisberg, Cindy ^a   Tajouri, Nadja ^b   Hainard, Alexandre ^a   Burkhard, Pierre R ^c   Lalive, Patrice H ^c,d   Turck, Natacha ^a  

^a Medical University Center   (Switzerland)

^b Division of Ophthalmology Neuchâtel Hospital   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Biomarkers; Isobaric labeling; Multiple sclerosis; Tears

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; TEAR PROTEIN; BIOLOGICAL MARKER; EYE PROTEIN; TEAR PROTEINS;

ADULT; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LACRIMAL FLUID; LACRIMAL FLUID LEVEL; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; SWITZERLAND; TANDEM MASS SPECTROMETRY; UNIVERSITY HOSPITAL; WESTERN BLOTTING; AGED; BIOSYNTHESIS; BODY FLUID; CEREBROSPINAL FLUID; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; BIOLOGICAL MARKERS; BODY FLUIDS; EYE PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEOMICS; TEARS; YOUNG ADULT;

EID: 84898547463     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300053     Document Type: Article

References (61)

1. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., Weinshenker, B. G., Multiple sclerosis. N. Engl. J. Med. 2000, 343, 938-952.
2. Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M. et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69, 292-302.
3. Lourenco, P., Shirani, A., Saeedi, J., Oger, J. et al., Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult. Scler. 2013, 19, 577-584.
4. Graber, J. J., Dhib-Jalbut, S., Biomarkers of disease activity in multiple sclerosis. J. Neurol. Sci. 2011, 305, 1-10.
5. Katsavos, S., Anagnostouli, M., Biomarkers in multiple sclerosis: an up-to-date overview. Mult. Scler. Int. 2013, 2013, 340508.
6. Orbach, R., Gurevich, M., Achiron, A., Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome. Mult. Scler. 2013.
7. Szalardy, L., Zadori, D., Simu, M., Bencsik, K. et al., Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. J. Neurol. Sci. 2013.
8. Gajofatto, A., Bongianni, M., Zanusso, G., Bianchi, M. R. et al., Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. Acta. Neurol. Scand. 2013.
9. Devos, D., Forzy, G., de Seze, J., Caillez, S. et al., Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. J. Neurol. 2001, 248, 672-675.
10. Calais, G., Forzy, G., Crinquette, C., Mackowiak, A. et al., Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult. Scler. 2010, 16, 87-92.
11. Tuck, M. K., Chan, D. W., Chia, D., Godwin, A. K. et al., Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 2009, 8, 113-117.
12. Dayon, L., Turck, N., Garci-Berrocoso, T., Walter, N. et al., Brain extracellular fluid protein changes in acute stroke patients. J. Proteome Res. 2011, 10, 1043-1051.
13. Dayon, L., Turck, N., Kienle, S., Schulz-Knappe, P. et al., Isobaric tagging-based selection and quantitation of cerebrospinal fluid tryptic peptides with reporter calibration curves. Anal. Chem. 2010, 82, 848-858.
14. Dayon, L., Turck, N., Scherl, A., Hochstrasser, D. F. et al., From relative to absolute quantification of tryptic peptides with tandem mass tags: application to cerebrospinal fluid. Chimia (Aarau) 2010, 64, 132-135.
15. Dayon, L., Pasquarello, C., Hoogland, C., Sanchez, J. C., Scherl, A., Combining low- and high-energy tandem mass spectra for optimized peptide quantification with isobaric tags. J. Proteomics 2010, 73, 769-777.
16. Gluck, F., Hoogland, C., Antinori, P., Robin, X. et al., EasyProt-an easy-to-use graphical platform for proteomics data analysis. J. Proteomics 2013, 79, 146-160.
17. Tan, H. T., Tan, S., Lin, Q., Lim, T. K. et al., Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol. Cell Proteomics 2008, 7, 1174-1185.
18. Tiberti, N., Hainard, A., Lejon, V., Robin, X. et al., Discovery and verification of osteopontin and Beta-2-microglobulin as promising markers for staging human African trypanosomiasis. Mol. Cell. Proteomics 2010, 9, 2783-2795.
19. Huang da, W., Sherman, B. T., Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44-57.
20. de Souza, G. A., Godoy, L. M., Mann, M., Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol. 2006, 7, R72.
21. Zhou, L., Zhao, S. Z., Koh, S. K., Chen, L. et al., In-depth analysis of the human tear proteome. J. Proteomics 2012, 75, 3877-3885.
22. Choy, C. K., Cho, P., Chung, W. Y., Benzie, I. F., Water-soluble antioxidants in human tears: effect of the collection method. Invest. Ophthalmol. Vis. Sci. 2001, 42, 3130-3134.
23. Green-Church, K. B., Nichols, K. K., Kleinholz, N. M., Zhang, L., Nichols, J. J., Investigation of the human tear film proteome using multiple proteomic approaches. Mol. Vis. 2008, 14, 456-470.
24. Dumortier, G., Chaumeil, J. C., Lachrymal determinations: methods and updates on biopharmaceutical and clinical applications. Ophthalmic Res. 2004, 36, 183-194.
25. Ozdemir, M., Temizdemir, H., Age- and gender-related tear function changes in normal population. Eye 2010, 24, 79-83.
26. Ananthi, S., Santhosh, R. S., Nila, M. V., Prajna, N. V. et al., Comparative proteomics of human male and female tears by two-dimensional electrophoresis. Exp. Eye Res. 2011, 92, 454-463.
27. Lolli, F., Franciotta, D., Oligoclonal bands in tears. Mult. Scler. 2010, 16, 760; author reply 761.
28. Forzy, G., Gallois, P., Hautecoeur, P., Multiple sclerosis and oligoclonal bands in tears. Ann. Biol. Clin. 1999, 57, 240.
29. Martino, G., Servalli, C., Filippi, M., Buscemi, M. et al., Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients. J. Neuroimmunol. 1993, 44, 149-155.
30. Fiorini, M., Zanusso, G., Benedetti, M. D., Righetti, P. G., Monaco, S., Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. Proteomics Clin. Appl. 2007, 1, 963-971.
31. Hansson, S. F., Simonsen, A. H., Zetterberg, H., Andersen, O. et al., Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann. Neurol. 2007, 62, 193-196.
32. Nakashima, I., Fujinoki, M., Fujihara, K., Kawamura, T. et al., Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann. Neurol. 2007, 62, 197-200.
33. Gajofatto, A., Bongianni, M., Zanusso, G., Benedetti, M. D., Monaco, S., Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? Int. J. Mol. Sci. 2011, 12, 7960-7970.
34. Sladkova, V., Mares, J., Lubenova, B., Zapletalova, J. et al., Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome. Neurol. Res. 2011, 33, 415-420.
35. Probst-Cousin, S., Kowolik, D., Kuchelmeister, K., Kayser, C. et al., Expression of annexin-1 in multiple sclerosis plaques. Neuropathol. Appl. Neurobiol. 2002, 28, 292-300.
36. Probst-Cousin, S., Heuss, D., Bergmann, M., Annexin-1 is no useful surrogate marker of multiple sclerosis - an immunocytochemical study of the cerebrospinal fluid. Clin. Neuropathol. 2011, 30, 18-24.
37. Cristante, E., McArthur, S., Mauro, C., Maggioli, E. et al., Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 832-841.
38. Ce, P., Erkizan, O., Gedizlioglu, M., Elevated HSP27 levels during attacks in patients with multiple sclerosis. Acta Neurol. Scand. 2011, 124, 317-320.
39. Aquino, D. A., Capello, E., Weisstein, J., Sanders, V. et al., Multiple sclerosis: altered expression of 70- and 27-kDa heat shock proteins in lesions and myelin. J. Neuropathol. Exp. Neurol. 1997, 56, 664-672.
40. Reindl, M., Knipping, G., Wicher, I., Dilitz, E. et al., Increased intrathecal production of apolipoprotein D in multiple sclerosis. J. Neuroimmunol. 2001, 119, 327-332.
41. Kroksveen, A. C., Aasebo, E., Vethe, H., Van Pesch, V. et al., Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J. Proteomics 2013, 78, 312-325.
42. Kroksveen, A. C., Guldbrandsen, A., Vedeler, C., Myhr, K. M. et al., Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol. Scand. Suppl. 2012, 90-96.
43. Lehmensiek, V., Sussmuth, S. D., Tauscher, G., Brettschneider, J. et al., Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler. 2007, 13, 840-849.
44. Aluru, S. V., Agarwal, S., Srinivasan, B., Iyer, G. K. et al., Lacrimal proline rich 4 (LPRR4) protein in the tear fluid is a potential biomarker of dry eye syndrome. PLoS One 2012, 7, e51979.
45. Boehm, N., Funke, S., Wiegand, M., Wehrwein, N. et al., Alterations in the tear proteome of dry eye patients-a matter of the clinical phenotype. Invest. Ophthalmol. Vis. Sci. 2013, 54, 2385-2392.
46. Matheis, N., Okrojek, R., Grus, F. H., Kahaly, G. J., Proteomics of tear fluid in thyroid-associated orbitopathy. Thyroid 2012.
47. Pieragostino, D., Agnifili, L., Fasanella, V., D'Aguanno, S. et al., Shotgun proteomics reveals specific modulated protein patterns in tears of patients with primary open angle glaucoma naive to therapy. Mol. Biosyst. 2013, 9, 1108-1116.
48. Fabian, T. K., Hermann, P., Beck, A., Fejerdy, P., Fabian, G., Salivary defense proteins: their network and role in innate and acquired oral immunity. Int. J. Mol. Sci. 2012, 13, 4295-4320.
49. Lee, Y., Kim, S. J., Park, H. D., Park, E. H. et al., PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression. Oncogene 2010, 29, 56-67.
50. Barderas, R., Mendes, M., Torres, S., Bartolome, R. A. et al., In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol. Cell. Proteomics 2013, 12, 1602-1620.
51. Naidoo, N., Cooperman, B. S., Wang, Z. M., Liu, X. Z., Rubin, H., Identification of lysines within alpha 1-antichymotrypsin important for DNA binding. An unusual combination of DNA-binding elements. J. Biol. Chem. 1995, 270, 14548-14555.
52. Santamaria, M., Pardo-Saganta, A., Alvarez-Asiain, L., Di Scala, M. et al., Nuclear alpha1-antichymotrypsin promotes chromatin condensation and inhibits proliferation of human hepatocellular carcinoma cells. Gastroenterology 2013, 144, 818-828, e814.
53. Choi, J. W., Liu, H., Shin, D. H., Yu, G. I. et al., Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics 2013.
54. Franciosi, L., Govorukhina, N., Fusetti, F., Poolman, B. et al., Proteomic analysis of human epithelial lining fluid by microfluidics-based nano-LC-MS/MS: a feasibility study. Electrophoresis 2013.
55. Lok, S. I., van Mil, A., Bovenschen, N., van der Weide, P. et al., Post-transcriptional regulation of alpha-1-antichymotrypsin by miR-137 in chronic heart failure and mechanical support. Circ. Heart Fail 2013.
56. Wagsater, D., Johansson, D., Fontaine, V., Vorkapic, E. et al., Serine protease inhibitor A3 in atherosclerosis and aneurysm disease. Int. J. Mol. Med. 2012, 30, 288-294.
57. Abraham, C. R., Selkoe, D. J., Potter, H., Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988, 52, 487-501.
58. Fraser, P. E., Nguyen, J. T., McLachlan, D. R., Abraham, C. R., Kirschner, D. A., Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 1993, 61, 298-305.
59. Han, Y., Jia, J., Jia, X. F., Qin, W., Wang, S., Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease. Neuro. Sci. Lett. 2012, 516, 232-236.
60. Guan, F., Gu, J., Hu, F., Zhu, Y., Wang, W., Association between alpha1-antichymotrypsin signal peptide -15A/T polymorphism and the risk of Alzheimer's disease: a meta-analysis. Mol. Biol. Rep. 2012, 39, 6661-6669.
61. Ottervald, J., Franzen, B., Nilsson, K., Andersson, L. I. et al., Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J. Proteomics 2010, 73, 1117-1132.